Lupin appoints Ramesh Swaminathan as CFO, Head Corporate Affairs

Published On 2020-03-27 04:00 GMT   |   Update On 2020-03-27 04:00 GMT

Mumbai: Pharma Major Lupin Limited (Lupin) announced the appointment of Ramesh Swaminathan as Chief Financial Officer and Head Corporate Affairs. Ramesh will also join the board as Executive Director.

Ramesh will lead Lupin's Finance, Investor Relations, Strategic Planning, Information Technology, Corporate Communications, and Administration functions.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, and Nilesh Gupta, Managing Director, Lupin said, "We are delighted to welcome Ramesh back to Lupin as Executive Director, Global CFO and Head Corporate Affairs. Ramesh played a very important role in Lupin for over a decade as part of our leadership team, to help grow our company multifold. We are very pleased to welcome him back at this crucial time as we accelerate our plans to take Lupin to the next level. In addition to his strong understanding of the pharmaceutical industry and our company, he brings us rich experience in digital strategy and innovation".

Ramesh brings to Lupin the rich experience of over 30 years. In addition to having worked with Lupin for more than a decade, he has also worked with reputed organizations in diverse industry sectors such as VST Industries Ltd, SPIC Group, Standard Chartered Bank, Henkel, and L&T.

Ramesh is a qualified Chartered Accountant, Cost Accountant, and Company Secretary and recipient of the prestigious Chevening Scholarship (UK). He also has an MBA from INSEAD. 

Read also: Lupin Receives International Sustainability Rating System (ISRS) Certification

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.

Read also: Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News